Thermo Fisher Scientific Inc. $TMO Stock Sold by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 19,787 shares of the medical research company’s stock after selling 3,036 shares during the period. Bank Pictet & Cie Europe AG’s holdings in Thermo Fisher Scientific were worth $13,357,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in TMO. Legacy Wealth Managment LLC ID lifted its holdings in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares during the period. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $25,000. Allied Private Wealth LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth $26,000. MBM Wealth Consultants LLC purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth $29,000. Finally, Pingora Partners LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc Casper sold 275 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $7.25 during mid-day trading on Tuesday, reaching $686.63. The company’s stock had a trading volume of 1,648,560 shares, compared to its average volume of 2,252,220. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $704.00. The business has a 50 day moving average price of $638.93 and a 200-day moving average price of $549.90. The firm has a market cap of $253.88 billion, a price-to-earnings ratio of 36.95, a PEG ratio of 2.89 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the company earned $4.28 earnings per share. The firm’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on TMO. Guggenheim assumed coverage on Thermo Fisher Scientific in a research note on Thursday, October 15th. They set a “buy” rating on the stock. Scotiabank began coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an “outperform” rating for the company. Barclays increased their target price on Thermo Fisher Scientific from $650.00 to $750.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Finally, BMO Capital Markets cut Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $654.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.